MAPT and early-onset autosomal dominant Alzheimer disease: Additional analyses were done using participants enrolled in studies at the Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) to determine the sensitivity of the short-form and long-form measures to AD neuroimaging biomarkers, including amyloid positron emission tomography (PET), tau PET, and magnetic resonance imaging (MRI) structural measures.